-
In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic sales growth guidance.
-
Although the CHAMPION-AF trial met all clinical endpoints, it did not act as a meaningful catalyst for the business outlook, and the contrast between bullish broker ratings and a Strong Sell Zacks Rank underscores growing concern around recent earnings estimate revisions.
-
We’ll now examine how the lowered 2026 organic sales growth guidance reshapes Boston Scientific’s investment narrative and future business expectations.
Find 50 companies with promising cash flow potential yet trading below their fair value.
Boston Scientific Investment Narrative Recap
To stay invested in Boston Scientific, you need to believe in its long term strength in electrophysiology and structural heart, even as near term expectations reset. The lowered 2026 organic sales growth guidance and underperformance in U.S. Electrophysiology and Watchman weigh on what had been key growth engines, while the biggest current risk is that earnings estimates continue to drift lower if these franchises do not reaccelerate.
The completed repurchase of 39,922,436 shares for US$2,000.11 million matters here because it interacts with weaker guidance and mixed CHAMPION AF sentiment. While the buyback reduces the share count and can support per share metrics, it sits alongside a Strong Sell Zacks Rank driven by recent negative earnings revisions, underscoring how capital returns are landing in a period of rising skepticism about the outlook for growth.
Yet beneath the optimism around FARAPULSE and WATCHMAN, investors should be aware that ongoing product recalls and slower EP growth could still…
Read the full narrative on Boston Scientific (it’s free!)
Boston Scientific’s narrative projects $25.8 billion revenue and $4.9 billion earnings by 2029.
Uncover how Boston Scientific’s forecasts yield a $72.25 fair value, a 39% upside to its current price.
Exploring Other Perspectives
Some analysts were assuming revenue could reach about US$28.0 billion with earnings of roughly US$5.5 billion, which is far more optimistic than consensus. Given the recent guidance cut and softer EP and Watchman performance, you should expect that both this bullish view and more cautious takes on CHAMPION driven LAA closure growth may evolve as fresh data and estimates come through.
